文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

玛伐凯泰:首个用于梗阻性肥厚型心肌病的心肌肌球蛋白抑制剂

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
PubMed 文献 · Eur Heart J · 2023-01-01

玛伐凯泰是首个靶向心肌肌球蛋白抑制剂,获FDA批准用于NYHA II-III级症状性梗阻性肥厚型心肌病成人患者。2/3期试验显示其耐受良好,降低左室流出道压差,改善运动能力和症状,并有利心脏重构。

要点

  • 玛伐凯泰靶向高收缩表型,获FDA批准用于症状性oHCM。
  • 临床试验显示降低左室流出道压差,改善运动能力和症状。
  • 可减少符合室间隔减容治疗指征的患者比例。

核心结论

  • 玛伐凯泰是首个靶向心肌肌球蛋白抑制剂,对症状性oHCM患者耐受良好并改善多项临床指标。

研究设计与样本

  • 综述已完成和正在进行的2期和3期临床试验中玛伐凯泰在症状性oHCM患者中的疗效和安全性数据。

主要发现

  • 玛伐凯泰耐受良好,降低左室流出道压差,改善运动能力和症状。
  • 患者报告结局和循环生物标志物等临床相关参数也有改善。
  • 多模态影像显示有利的心脏重构证据。
  • 玛伐凯泰大幅减少符合室间隔减容治疗指征的oHCM患者。

临床怎么用

  • 玛伐凯泰可用于NYHA II-III级症状性oHCM成人患者。
  • 长期扩展研究可能有助于确定其在当前oHCM管理流程中的定位。

局限性

  • 长期扩展研究可能有助于解决与背景治疗的相互作用及疾病修饰潜力等问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the US Food and Drug Administration for the treatment of adults with symptomatic New York Heart Association Classes II and III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten was developed to target the hyper-contractile phenotype, which plays a critical role in the pathophysiology of the disease. In Phase 2 and 3 clinical trials, mavacamten was well tolerated, reduced left ventricular outflow tract gradients, improved exercise capacity and symptoms, and was associated with improvements in other clinically relevant parameters, such as patient-reported outcomes and circulating biomarkers. In addition, treatment with mavacamten was associated with evidence of favourable cardiac remodelling in multi-modality imaging studies. Mavacamten substantially reduced guideline eligibility for septal reduction therapy candidates with oHCM and drug-refractory symptoms. In this article, the available efficacy and safety data from completed and ongoing clinical studies of mavacamten in patients with symptomatic oHCM are reviewed. Longer term extension studies may help address questions related to the positioning of mavacamten in current oHCM management algorithms, interactions with background therapy, as well as the potential for disease modification beyond symptomatic relief of left ventricular outflow tract obstruction.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Braunwald E, Saberi S, Abraham TP, et al. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J. 2023. PMID: 37804245. doi:10.1093/eurheartj/ehad637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。